Thursday, 18 Jan 2018

You are here

Gouts' Increasing Hospitalizations and Poor Management

Numerous studies have shown that gout hospitalizations have increased in the last decade. Also worrisome is a new studiy showing that patients admitted to the hospital are less likely to have received recommended urate-lowering treatment (ULT). (Abstract OP0262 - http://buff.ly/2roN7SF)

Dehlin and Swedish researchers have analyzed the Western Swedish Health Care Region register to identify gout hospitalizations between 2000-2013. They found the annual hospitalization rate for gout increased from 12.2 to 16.7 per 100 000 adults, with a resultant 56% increase in healthcare costs.

Moreover, these patients were less likely to receive ULT -  only 19 to 27% had been on ULT in the 6 months preceding their hospitalization. This considerable lack of treatment is seen as yet another reason for the growth in gout hospitalizations in Sweden.

A second study, examined whether nurse-led management of gout using EULAR guidelines and treat to target principles significantly improved patient outcomes compared to standard general practitioner care (http://buff.ly/2sBCxvY).

Over 2 years, they studied 517 patients who received usual care by general practitioners (GP) or nurse-led care.  Nurse lead care were more likely to achieve SUA targets, more likely to be prescribed ULT (97% vs. 54%), more escalation of  allopurinol therapy (470 vs. 240 mg), fewer gout attacks, and a nearly 75% reduction in tophus size. 

The results of these studies have immediate applicability to gout populations and public welfare and healthcare costs. 

 

 

 

Disclosures: 
The author has received research/grant financial support on this subject

Add new comment

More Like This

New BSR 2017 Gout Guidelines (Best of 2017)

The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.

Allopurinol Dose Escalation is Safe with Severe CKD

Hypertension, nephrolithiasis and chronic kidney disease (CKD) commonly associates with gout.  While there is a clear need to dose adjust NSAIDs and colchicine in those with CKD, there is some debate about the need to dose adjust when using allopurinol with CKD.

Risk of Gout Onset and Flare Linked to Urate Levels

Serum uric acid (SUA) levels are clearly linked to gout. Researchers from Harvard have systemically reviewed the literature to quantify the risk of onset and flare with varying levels of SUA.

Literature review identified 8 eligible articles reporting gout incidence and 18 articles reporting recurrent gout rates in the context of SUA levels.

Febuxostat Works in Early Gout But Fails to Protect from Xray Damage

Dalbeth and colleagues have published a novel report in Arthritis & Rheumatology, novel in that it is a trial of early gout patients that looks at clinical and radiographic outcomes. They showed that febuxostat improves magnetic resonance imaging (MRI) measures of synovitis and reduced gout flares, but failed to alter X-ray progression with 2 years follow-up. 

Gout Associated with Work Absenteeism

Annals of Rheumatic Disease reports that gout is associated with higher work absenteeism and thus, increased costs for society due to productivity loss.

Using Swedish national and regional registry data from 2000 to 2012, researchers studied 4571 gout patients of working age, and compared them to 22 482 population controls and assessed patient characteristics, work-loss days (absenteeism), sick leave and disability.